Apoptosis and Targeted Cancer Therpeutics Flashcards
What cancer was bcl-2 antisense therapy tried in
Metastatic melanoma
What cancer was siRNA for bcl2 used in
breast tumours –> caused robust repression in mice with xenograft
Showed apoptosis and autophagic death in cells in combination with doxorubicin
What is doxorubicin
A drug that induces functionally active CD95
What is usually overexpressed in c-myc tumours
Bcl-2 –> enables c-myc tumours to evade oncogene induced sensecence!
WHat mouse model is used eto show c-myc and bcl-2 coverexpressoin
Burkitt’s lymphoma in mice
Howvever c-myc overexpression without bcl-2 just causes masive apoptssi and tumour regression
Name the 3 BH3 mimetics
Navitoclax
Ventoclax
What are the differences between Naviotclax and ventoclax
Navitoclax inhibits BCL-XL and bcl-2
Ventoclax only inhibits BCL-2
Which anto-apoptotic protein can most BH3 mimetics not target
MCL-1 –> howver a specified MCL-1 antagonist has been developed
Where have bim peptides been shown to be effacious
in mouse models of AML
What helix blocks the BH3 groove in Bax
alpha 9 –> confirmational shape change allows its exposure before it can oligomerise and nsert into the membrane
Where is the additional BH3 binding site on Bax
between alpha helices 1 and 6
What molecules aim to bind to the BH3 additional binding site
Bax Activating Molecules (BAM) –> bind to the rear BH3 binding pocket and can killl cells
Why is TRAIL overexpressed many cancer cells
As TRAIL can enhance PI3K Signalling and enhance migration and invasion
What occurs when FADD Is releaed from the TRAIL complex
forms Complex 2 –> recruits TRADD which leads to the potent aftivation of NF-kB
Also recruity TRAF2 which activates the MAPkK pathway
What decoy trail receptor is upregulated in AML
Trail 3 esp. in CSCs
Agonistic Ab binding targeted to Trail 2 is the most successful!!